Novaliq GmbH is a drug delivery company located in the Heidelberg Technology Park, Germany. They develop innovative pharmaceutical formulations based on semifluorinated alkanes (SFAs).
Their patented SFAs can be used in various routes of administration for the transport of drugs or oxygen for therapeutic purposes. Novaliq currently develops novel ophthalmic and dermatological products as well as solutions for organ preservation, based on the unique physicochemical properties of SFA.
Their first and preservative free eye drop product (OTC) is NovaTears® for the relief of discomfort under dry eye syndrome. The product is available in standard multi dose units.
Besides the development of its own products and licensing them to pharmaceutical distributors, Novaliq is offering its SFA technology as a delivery platform for external co-development cooperations.